| Typicality: | 0.400 |
| Saliency: | 0.353 |
| as a single agent | 7 | manner |
| in combination with atezolizumab | 6 | other |
| for patients with chronic cerebral hypoperfusion | 3 | other |
| trial → test → tolerability | 13 |
| trial → study → tolerability | 5 |
| trial → demonstrate → tolerability | 5 |
| trial → confirm → tolerability | 4 |
| negative | neutral | positive |
| 0.035 | 0.652 | 0.313 |
| Raw frequency | 27 |
| Normalized frequency | 0.353 |
| Modifier score | 0.500 |
| Perplexity | 468.090 |